Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN versus ZMAX.
ERYTHROCIN vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also exhibits anti-inflammatory and prokinetic effects via motilin receptor agonism.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6 hours.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults; may prolong to 4-6 hours in hepatic impairment or neonates.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily eliminated via biliary excretion as unchanged drug and metabolites; approximately 2-5% excreted renally as active drug, 15-20% as metabolites; up to 30% excreted in feces.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic